Anti-Human CD123/IL3RA Antibody (SAA0045)

Catalog No.

FHD72510

Species reactivity

Human

Host species

Mouse

Isotype

IgG1, kappa

Clonality

Monoclonal

Conjugation

Unconjugated

Target

IL-3R subunit alpha, IL-3 receptor subunit alpha, CD123, Interleukin-3 receptor subunit alpha, IL3R, IL-3R-alpha, IL3RA, IL-3RA

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P26951

Applications

FCM, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA0045

Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions., PMID:40429716

Establishment of a novel human basophil cell line for functional analysis and in vitro allergy testing., PMID:40187962

Combining CD64 and CD123 Biomarkers for Sepsis Early Diagnosis and Severity Assessment via PD-L1 Antibody Affinity Microfluidic (PAAM) Chip in Trace Clinical Samples., PMID:40177943

Immunotherapies Targeting CD123 and CD303: A New Frontier in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm., PMID:40141368

Evaluation of Dendritic Cell Subpopulations Frequency in COVID-19 Patients and their Correlation with Disease Severity., PMID:40130356

Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632)., PMID:40119158

A review of antibody-based immunotherapy clinical trials for adult acute myeloid leukemia (AML): monoclonal antibodies (mAbs) and beyond., PMID:40069930

Clinical, Histopathological, and Therapeutic Features in Lupus Erythematosus Tumidus: A Retrospective Study., PMID:39947587

Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality., PMID:39915004

A novel label-free method to determine equilibrium dissociation constants of antibodies binding to cell surface proteins., PMID:39870691

Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies., PMID:39864030

The CD123 antibody-drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia., PMID:39830370

Acute myeloid leukemia management and research in 2025., PMID:39656142

Hairy cell leukemia (HCL) and HCL-like disorders: present, emergent treatment options and future directions., PMID:39535173

Advancements in leukemia management: Bridging diagnosis, prognosis and nanotechnology (Review)., PMID:39364739

Current status and research directions in acute myeloid leukemia., PMID:39300079

Good manufacturing practice-grade generation of CD19 and CD123-specific CAR-T cells using piggyBac transposon and allogeneic feeder cells in patients diagnosed with B-cell non-Hodgkin lymphoma and acute myeloid leukemia., PMID:39192973

Olverembatinib combined with inotuzumab ozogamicin in relapsed refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: A case report., PMID:39029009

Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia., PMID:38904305

Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells., PMID:38819256

TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates., PMID:38768424

[Preparation of a dual-specific antibody targeting human CD123 and exploration of its anti-acute myeloid leukemia effects]., PMID:38716593

Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study., PMID:38629176

Identification of Specific Cell Surface Markers on Immune Cells of Squirrel Monkeys (Saimiri sciureus)., PMID:38566886

Erythema Multiforme-Like Fixed Drug Eruption During Azathioprine and Hydroxychloroquine Treatment for Systemic Lupus Erythematosus Mimicking Rowell Syndrome: A Rare and Challenging Clinical Scenario., PMID:38494929

CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123., PMID:38492495

Immunophenotypic characterization of leukemic stem cells in acute myeloid leukemia using single tube 10-colour panel by multiparametric flow cytometry: Deciphering the spectrum, complexity and immunophenotypic heterogeneity., PMID:38456256

Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study., PMID:38423051

Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123., PMID:38338733

Case report: Kikuchi-Fujimoto disease: unveiling a case of recurrent fever and enlarged cervical lymph nodes in a young female patient with a literature review of the immune mechanism., PMID:38313434

Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile., PMID:38266153

Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia., PMID:38075241

Plasmacytoid Dendritic Cells, the Expression of the Stimulator of Interferon Genes Protein (STING) and a Possible Role of Th17 Immune Response in Cervical Lesions Mediated by Human Papillomavirus., PMID:38031606

Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas., PMID:37998391

Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy., PMID:37773046

Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations., PMID:37729719

15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges., PMID:37706583

Update on immune-based therapy strategies targeting cancer stem cells., PMID:37698048

Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies., PMID:37673048

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia., PMID:37648862

Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia., PMID:37647601

Twenty-four-color full spectrum flow cytometry panel for minimal residual disease detection in acute myeloid leukemia., PMID:37533738

Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia., PMID:37524506

Use of Payload Binding Selectivity Enhancers to Improve Therapeutic Index of Maytansinoid-Antibody-Drug Conjugates., PMID:37493255

The Contribution of Multiplexing Single Cell RNA Sequencing in Acute Myeloid Leukemia., PMID:37489448

CSL362 potently and specifically depletes pDCs invitro and ablates SLE-immune complex-induced IFN responses., PMID:37456846

Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies., PMID:37452102

Blastic Plasmacytoid Dendritic Cell Neoplasm., PMID:37156483

Can Immune Therapy Cure Acute Myeloid Leukemia?, PMID:36949279

Towards standardizing basophil identification by flow cytometry., PMID:36938328

Document Download

Anti-Human CD123/IL3RA Antibody (SAA0045).pdf